Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | BLM | P54132 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | METAP1 | P53582 | 1/20 | 0.41 |
| ▸ | ALPL | P05186 | 1/20 | 0.41 |
| ▸ | CDC25A | P30304 | 1/20 | 0.41 |
| ▸ | CDC25B | P30305 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2880191 | 0.79 | LMNA (0.54) | RAB9ANPC1SMN1; SMN2RXFP1GAA | |
| SCHEMBL17390354 | 0.79 | RXFP1 (0.40) | RAB9ANPC1SMN1; SMN2RXFP1KDM4E | |
| SCHEMBL5777669 | 0.79 | JAK1 (0.39) | RAB9ANPC1SMN1; SMN2RXFP1GAA | |
| SCHEMBL1566862 | 0.79 | RAB9A (0.52) | RAB9ANPC1SMN1; SMN2RXFP1GAA | |
| SCHEMBL21481533 | 0.78 | NR3C1 (0.52) | RAB9ANPC1SMN1; SMN2RXFP1POLB | |
| SCHEMBL24251779 | 0.78 | BLM (0.42) | KDM4EGAABLMKMT2APOLB | |
| SCHEMBL6826283 | 0.76 | ALDH1A1 (0.50) | RAB9ANPC1KDM4EGAABLM | |
| SCHEMBL718382 | 0.76 | SIGMAR1 (0.49) | RAB9ANPC1SMN1; SMN2RXFP1GAA | |
| SCHEMBL7223042 | 0.75 | CA12 (0.39) | RXFP1GAAPOLBLMNAMETAP1 | |
| SCHEMBL23134022 | 0.75 | RAB9A (0.46) | RAB9ANPC1SMN1; SMN2KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137677-A1 | PROTACS USEFUL AGAINST THE MAIN PROTEASE SARS-COV-2 | TOCRIS COOKSON LTD (GB) | 2026-05-21 | — | — | US | disclosed |
| EP-4701735-A1 | HETEROCYCLIC DERIVATIVE AS MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITOR | Nested Therapeutics, Inc. (US) | 2026-03-04 | — | — | EP | disclosed |
| WO-2025226862-A1 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| US-20250289811-A1 | HETEROCYCLIC DERIVATIVES AS MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | NESTED THERAPEUTICS, INC. | 2025-09-18 | — | — | US | disclosed |
| EP-4598914-A1 | PROTACS USEFUL AGAINST THE MAIN PROTEASE SARS-COV-2 | Tocris Cookson Limited (GB) | 2025-08-13 | — | — | EP | disclosed |
| US-20250195495-A1 | RNA Virus Inhibitor Compounds and Uses Thereof | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2025-06-19 | — | — | US | disclosed |
| CN-119954831-A | Pyrimidopyrazoles, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2025-05-09 | — | — | CN | disclosed |
| EP-4514471-A1 | HETEROCYCLIC DERIVATIVES AS MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | Nested Therapeutics, Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| US-12186309-B2 | RNA virus inhibitor compounds and uses thereof | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2025-01-07 | — | — | US | disclosed |
| WO-2024226579-A9 | HETEROCYCLIC DERIVATIVE AS MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITOR | NESTED THERAPEUTICS, INC. (US) | 2024-12-26 | — | — | WO | disclosed |
| US-10562906-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190241576-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-08 | — | — | US | disclosed |
| WO-2019023468-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2019-01-31 | — | — | WO | disclosed |
| US-20050165062-A1 | Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2005-07-28 | — | — | US | disclosed |
| US-6870056-B1 | Substitituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2005-03-22 | — | — | US | disclosed |
| US-6867217-B1 | Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2005-03-15 | — | — | US | disclosed |
| CN-1378534-A | Substituted polycyclic aryl and heteroaryl pyridones for selective inhibition of the coagulation cascade | PHARMACIA CO (US) | 2002-11-06 | — | — | CN | disclosed |
| EP-1178964-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRIDONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | Pharmacia Corporation (US) | 2002-02-13 | — | — | EP | disclosed |
| WO-2001087842-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRIDONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2001-11-22 | — | — | WO | disclosed |
| WO-2000069826-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRIDONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165062-A1 | Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade | TFPI, PLAT, TFPI2 | RAB9A 4090/4885NPC1 3928/4885SMN1; SMN2 3799/4885 |
| US-10562906-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | RAB9A 3462/4885NPC1 4595/4885SMN1; SMN2 1145/4885 |
| US-20190241576-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | RAB9A 3462/4885NPC1 4595/4885SMN1; SMN2 1145/4885 |
| US-20250195495-A1 | RNA Virus Inhibitor Compounds and Uses Thereof | NSUN3, EIF2AK2, NSUN2 | RAB9A 1943/4885NPC1 503/4885SMN1; SMN2 1395/4885 |
| US-12186309-B2 | RNA virus inhibitor compounds and uses thereof | NSUN3, EIF2AK2, NSUN2 | RAB9A 1943/4885NPC1 503/4885SMN1; SMN2 1395/4885 |
| US-20260137677-A1 | PROTACS USEFUL AGAINST THE MAIN PROTEASE SARS-COV-2 | XIAP, MDM2, SARS1 | RAB9A 1660/4885NPC1 3028/4885SMN1; SMN2 1397/4885 |
| US-20250289811-A1 | HETEROCYCLIC DERIVATIVES AS MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | MAPK1, MAP3K1, MAPK3 | RAB9A 914/4885NPC1 4497/4885SMN1; SMN2 4521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.